- Blog
Biotech IOR: Importing Advanced Therapies, Biologics and Lab Samples Globally
5 Minutes
August 20, 2026
Last updated: August 20, 2026
Streamline global clinical trial logistics with a dedicated Biotech IOR. Prevent customs delays for advanced therapies, biologics, and lab samples with TecEx Medical.
In the biopharmaceutical sector, Biotech IOR (Importer of Record) services are no longer just an administrative detail, they are a critical safeguard for global clinical trials. Advanced therapy medicinal products (ATMPs), such as cell and gene therapies, along with biologics and patient lab samples, are exceptionally perishable, temperature-sensitive, and subject to intense regulatory oversight by agencies such as the U.S. FDA, the EMA, and local Ministries of Health. In this high-stakes environment, a single customs delay not only causes administrative friction but also often results in complete batch destruction, compromised patient safety, or missed clinical trial site activation dates.
Navigating Time-Sensitive Radiopharmaceutical Imports | The Use Case for Biotechs Requiring an IOR
A leading biotech company reached out to TecEx Medical recently for continued support and assistance with their time-critical radiopharmaceutical imports. Radiopharmaceutical shipments carry strict viability windows and typically must arrive at clinical sites within 96 hours, demanding exceptional care, regulatory expertise, and speed.
TecEx Medical facilitated these crucial imports for a multinational, multicenter, prospective, randomized, controlled, open-label Phase 3 study evaluating lutetium (177Lu) rosopatamab tetraxetan combined with standard of care versus standard of care alone in patients with PSMA-positive metastatic castration-resistant prostate cancer. Transporting Investigational Product (IP) from Austria to clinical trial sites in South Korea and Singapore posed, the project presented rigid delivery windows and strict local regulatory frameworks. The TecEx Medical team ensured zero customs delays, smooth handoffs, and flawless execution between all international stakeholders.
“Our team at TecEx Medical, along with our trusted in-country partners, stepped up to provide a true 24/7 solution for these time-critical shipments. From providing real-time updates back to the client’s home base to facilitating seamless weekend customs clearances, we made sure every hand-off was flawless so these life-saving therapies arrived on site without a moment’s delay.”
- Marjomale Dalhouzie (Product and Research Innovation Specialist)
The TecEx Medical Solution
Every clinical trial that crosses an international border creates an import-compliance challenge long before it creates a physical logistical problem. A legally recognized entity must act as the importer of record in each destination country, hold the proper licenses, classify and value the goods accurately, and take full legal accountability before local customs authorities.
TecEx Medical serves as that vital compliance layer. Operating not as a freight forwarder or a CRO, but as a dedicated Biotech IOR and EOR specialist, TecEx Medical assumes full compliance liability across 100+ countries. This coverage extends to every commodity a trial requires from Investigational Medicinal Products (IMP), medical devices, eCOA/PRM hardware, biosamples, laboratory equipment, and ancillary consumables. How this value translates depends on where an organization sits in its lifecycle:
| Biotech Tier | Specific Need | How TecEx Medical Solves It |
|---|---|---|
| Small / Emerging | Fast, low-capital entry into overseas trial sites without establishing local legal entities. | Serves as a 100% Biotech IOR/EOR, assuming legal importer liability and supplying required in-country licenses and permits. This allows trials to launch rapidly in non-presence markets without setting up local foreign subsidiaries or burdening trial sites. Additionally, provide advice on regions and markets regarding regulatory hurdles and turnaround time to get receive ministry approvals. |
| Mid-Sized | Scaling Phase 2/3 trials across multiple global regions (LATAM, APAC, EU) simultaneously. | Delivers a single compliance point of contact across 100+ countries with standardized customs SOPs. Additionally provides VAT recovery and duty/HTS optimization, turning tax management into a recoverable cost rather than an overhead expense. Additionally, provide advice on regions and markets regarding regulatory hurdles and turnaround time to get receive ministry approvals. |
| High-Value / Complex Modalities (Radiopharma, CGT) | Ultra-high-value, time-sensitive shipments where import permits, declared values, and classifications carry high financial, tax, and audit risks. | Provides precise customs valuation and classification for high-value consignments, comprehensive Biotech IOR/EOR coverage in non-presence markets, and seamlessly coordinated clearances aligned with the freight provider's delivery windows. Additionally, provide advice on regions and markets regarding regulatory hurdles and turnaround time to get receive ministry approvals. |
What is a Biotech?
A biotechnology (biotech) company harnesses cellular and biomolecular processes such as gene editing, monoclonal antibodies, recombinant DNA, and living cell therapies to discover, develop, and commercialize innovative medical treatments.
Unlike traditional pharmaceutical firms that rely primarily on chemical compounds, biotechs specialize in living organisms or complex biologic agents.
Types of Biotechs
Understanding where a biotech sits in its growth cycle helps clarify its unique import and export requirements.
Small Biotechs
Early-stage companies often focus heavily on science while accidentally overlooking local import laws right up until a patient sample or viral vector is stranded at customs. Utilizing a third-party Biotech IOR partnership saves critical early-stage capital and prevents costly trial delays.
Medium Biotechs
Medium sized developers scaling Phase 2 and 3 trials globally must transition away from fragmented, early-stage CRO logistics. Establishing a structured, multi-regional Biotech IOR network prevents regulatory bottlenecks across expanding international site lists.
Large Biotechs
Large enterprises manage high-density lab sample logistics, bulk investigational products, and complex regulatory filings across dozens of global operating subsidiaries simultaneously.
Scientific applications also define biotech categories by color for example Red Biotechs (the largest sector) focusing on human health, vaccines, and therapeutics, Green Biotechs targeting agricultural advancements, and White Biotech driving industrial bio-manufacturing. Across clinical development, these organizations range from pre-clinical startups testing niche therapies to multinational biopharmas managing enterprise supply chains.
Challenges of Importing Advanced Therapies, Biologics, and Lab Samples Globally
Bringing complex biological therapies across borders involves significant operational and regulatory hurdles.
Regulatory and Compliance Bottlenecks
- Cross-Border Customs and Trade Controls: Moving live biologics and cell lines internationally requires meticulous documentation, specialized import/export permits, and an established local entity acting as the designated Biotech IOR.
- Constantly Shifting Global Regulations: Keeping pace with evolving requirements from regulatory bodies like the FDA and EMA creates friction, particularly around ATMPs, AI-driven drug discovery frameworks, and local health authority approvals.
Supply Chain and Cold Chain Vulnerabilities
- Temperature Excursion Risks: Biologics, mRNA platform therapies, and live-cell treatments require continuous cold-chain maintenance, ranging from deep-frozen (-80°C) to cryogenic (-196°C) conditions. A single thermal excursion during transit can render an entire consignment unusable.
- Reliance on Single-Source CDMOs: Relying on a single CDMO for specialized raw materials leaves biotechs vulnerable to unexpected supply disruptions, capacity constraints, or regional manufacturing delays.
Clinical Trial Logistics
- Patient Sample Traceability: For autologous therapies in which a patient’s own cells are collected, engineered, and reinfused, maintaining an unbroken Chain of Identity (CoI) and Chain of Custody (CoC) across international borders is legally required.
- Secondary Labeling and Country-Specific Rules: Multi-country clinical trials must navigate complex local labeling rules, including multilingual compliance and specialized cryo-compatible tags engineered to survive ultra-low temperatures.
Navigating the global trade and regulatory landscape for advanced therapies, biologics, and lab samples requires precision that matches the science itself. Whether you are an emerging biotech launching a Phase 1 trial, a mid-sized biopharma scaling bulk CMC movements to central clinical depots, or an enterprise developer managing time-sensitive radiopharmaceuticals, customs delays and regulatory bottlenecks pose a direct threat to trial timelines and patient outcomes.
By leveraging a dedicated, specialized Biotech IOR partner, biotechs can bypass the administrative burden of setting up costly local legal entities in destination countries. TecEx Medical ensures unbroken cold-chain compliance, 24/7 proactive tracking, and pre-cleared customs lanes, turning complex cross-border logistics from a point of vulnerability into a seamless, reliable driver of global clinical trial success.
